Jounce Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Jounce Therapeutics's estimated annual revenue is currently $89.3M per year.(i)
  • Jounce Therapeutics's estimated revenue per employee is $464,844
  • Jounce Therapeutics's current valuation is $321.8M. (January 2022}

Employee Data

  • Jounce Therapeutics has 192 Employees.(i)
  • Jounce Therapeutics grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide longlasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS. For more information, please visit We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients lives.

keywords:Biotechnology,Enterprise Software,Healthcare,Human Resources Hr,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Jounce Therapeutics News

2017-01-27 - Jounce Therapeutics prices IPO beyond expectations (Updated)

The early stage biotech company, with a focus on cancer immunotherapy and targeted therapeutics, has raised $102 million in private funding to date, from investors such as Third Rock. Jounce is listed on the NASDAQ Capital Market under the ticker symbol “JNCE”. Jounce’s lead compound, JTX-2011 ...

2020-09-01 - Gilead inks $805M in-licensing deal with Jounce for preclinical immuno-oncology drug

Shares of Jounce rose 65.5% on the Nasdaq when markets opened Tuesday and were still up more than 47% in late-morning trading. Gilead’s shares fell by 2.5%. JTX-1811 is a monoclonal antibody that targets the chemokine receptor CCR8, thereby depleting immunosuppressive tumor-infiltrating T-regul ...

2021-03-09 - Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000, ...

24-Aug-19 - Do Institutions Own Shares In Jounce Therapeutics, Inc. (NASDAQ:JNCE)?

A look at the shareholders of Jounce Therapeutics, Inc. (NASDAQ:JNCE) can tell us which group is most powerful. Insiders often own a large ...

31-Aug-19 - Jounce Therapeutics to Present at Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the ...

12-Sep-19 - Why Jounce Therapeutics, Inc. (JNCE) Shares Are Crashing -4.29 Percent Today

Jounce Therapeutics, Inc. (NASDAQ:JNCE) is one of the worst performers on the stock market today. At current price of $3.57, the shares have ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding